GenScript Reports 27.3% Revenue Growth

GenScript Biotech Corporation reported first-half 2026 revenue of approximately US$404.2 million, up 27.3% year over year, and adjusted net profit of approximately US$62.5 million, up 203.3%. The AI-enabled drug discovery business doubled year over year for the third consecutive half-year period, driven by demand from AI-focused biotech and pharmaceutical companies. Gene-to-Protein accounted for about 66% of GenScript Biotech Corporation revenue, which grew 28.8% to US$319.0 million. ProBio CDMO revenue increased 34.2% to US$61.1 million with new orders up 54%, while its adjusted operating loss narrowed 22.5% to US$24.3 million. Bestzyme revenue grew 7.4% to US$30.4 million. The company expects continued growth and profitability improvement in the second half of 2026.